Welcome to the February edition of BioMatrix Abstract!

Welcome to the February edition of BioMatrix Abstract!

BioMatrix Abstract informs readers of our leading efforts in the specialty pharmacy space while providing updates on relevant legislative efforts, research initiatives, and current events in healthcare.


New Website and New Look?

Our new website has launched! We’ve updated our look, streamlined our content, and made things easier to find.

Check it out!


Mary Munson Runge: A Trailblazer in Pharmacy?

As we celebrate Black History Month, it’s important to pause and remember the achievements by Black Americans and their critical, central role in United States history. Here, we spotlight Mary Munson Runge—a pharmacist and advocate.

Read more.


Neonatal Alloimmune Thrombocytopenia (NAIT): Signs, Symptoms, and Treatment Options?

Neonatal alloimmune thrombocytopenia (NAIT) occurs when the mother's immune system forms antibodies against fetal platelets leading to thrombocytopenia (a low platelet count). Here we discuss signs, symptoms, prevention, and treatment.

Read more.


BioMatrix on the Move!

Upcoming Events?

Catch up with BioMatrix at these upcoming events. We can't wait to see you!

  • 3/13: Ultra EMG/AANEM in San Diego, CA?
  • 3/21: San Diego Allergy Society Conference in San Diego, CA?
  • 3/23 to 3/27: National Home Infusion Association in Austin, TX?


BioMatrix Was Proud to Attend and Support These Meetings

Thanks to all who participated!

  • 2/2 to 2/4: Texas Neurological Society (TNS) Annual Winter Conference in Austin, TX??
  • 2/22 to 2/23: Carrell Krusen Neuromuscular Symposium in Dallas, TX


IVIG and SCIG Specialty Infusion Services

Immunoglobulin (IG) is used to treat multiple conditions. It helps calm the immune system and reduce inflammatory flare ups associated with autoimmune and immune-mediated disorders. It can also be used to increase the likelihood of a successful transplant for patients prior to an organ transplant (desensitization). It’s most commonly given through a drip into a vein (IVIG) or sometimes as an injection into the skin (SCIG).?

As a specialty infusion pharmacy, our clinical teams have extensive training and experience with infusion therapies, rare diseases, and complex medical conditions.?

Our clinical staff coordinates with pharmacists, healthcare providers, and other caregivers to determine the best place for patients to receive their infusion. Whether administering in-home with assistance from one of our home infusion nurses, in one of our ambulatory infusion suites, or in-office our nurses work with patients and providers to make therapy administration as safe and convenient as possible.?

Learn more about our IVIG and SCIG specialty infusion services.


Copay Accumulators

About half of commercially covered lives are in plans that utilize some kind of copay adjustor model. More plans are also using third-party vendors like SaveOnSp or PrudentRx for copay cards. With these vendors, the insurer determines a brand drug with a copay card as a “non-essential health benefit.” The patient on the brand drug is then turned over to the vendor who then controls the copay card, the copayment amount, and the authorization of the drug. In all these plans, copay drug cards go to profiting the PBM and insurer and not toward a patient’s deductible or out-of-pocket costs.

Read more: More plans use third party vendors for copay cards.


Surprise Billing

Surprise Billing disputes are getting backlogged at the federal level as case loads rise on the heels of the No Suprises Act. The federal government, who sets up the independent dispute resolution (IDR), has been overloaded with over 13x the number of anticipated cases. For the third of cases resolved, providers won 77% of payment determinations. Patients, however, have been the biggest winners with more than ten million surprise bills prevented in the first 6 months of 2023 alone.

Read more: Patients biggest winner in No Surprises Act.


Congress

The Senate Committee on Health, Education, Labor, and Pensions (HELP Committee) held a hearing asking pharmaceutical manufacturers why US drugs are so much more expensive than those overseas. Executives from Bristol Myers Squibb, Johnson & Johnson, and Merck stated that faster access and other health care spending, like PBMs, explains the difference in cost. Congress claimed the three drug companies make more money selling popular drugs in the US than in the rest of the world combined. The back and forth failed to yield any true outcome, nor a clear winner.

Read more: Pharmaceutical manufacturers in hot seat at senate hearing.


Never Miss an Edition of BioMatrix Abstract!

Click here to get BioMatrix Abstract sent to your email once monthly!


BioMatrix is a nationwide, independently-owned infusion pharmacy with decades of experience supporting patients on specialty medication.

Visit our website.


要查看或添加评论,请登录

社区洞察

其他会员也浏览了